Good Clinical Data For SRF388, An Innovative Lung Cancer Drug, With Patients Stable For
Flexible intelligent device allows stroke patients to walk freely
New Treatment For Childhood Brain Tumours, Tovorafenib, Shows Promising Results With An Efficiency Rate Of 91%!
More Significant Survival Benefit For Non-Small Cell Lung Cancer Patients Under 55 Years Of Age, Also Using Immunotherapy!
New Lymphoma Drug Approved! Half Of The Patients Had Significant Tumour Regression
Genkore Announces Collaboration With Us Company On In Vivo Gene Editing Therapies
